These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38942989)

  • 1. Synergy of retinoic acid and BH3 mimetics in MYC(N)-driven embryonal nervous system tumours.
    Seiboldt T; Zeiser C; Nguyen D; Celikyürekli S; Herter S; Najafi S; Stroh-Dege A; Meulenbroeks C; Mack N; Salem-Altintas R; Westermann F; Schlesner M; Milde T; Kool M; Holland-Letz T; Vogler M; Peterziel H; Witt O; Oehme I
    Br J Cancer; 2024 Sep; 131(4):763-777. PubMed ID: 38942989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
    Tanos R; Karmali D; Nalluri S; Goldsmith KC
    BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth.
    Lamers F; Schild L; den Hartog IJ; Ebus ME; Westerhout EM; Ora I; Koster J; Versteeg R; Caron HN; Molenaar JJ
    Eur J Cancer; 2012 Nov; 48(16):3093-103. PubMed ID: 22366560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
    Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
    Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.
    Zoeller JJ; Vagodny A; Daniels VW; Taneja K; Tan BY; DeRose YS; Fujita M; Welm AL; Letai A; Leverson JD; Blot V; Bronson RT; Dillon DA; Brugge JS
    Breast Cancer Res; 2020 Nov; 22(1):132. PubMed ID: 33256808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of BH3 mimetics as a combination therapy with irradiation in head and neck squamous cell carcinoma.
    Korelin K; Oostveen M; Wahbi W; Ianevski F; Cavalcante B; Turunen L; Belevich I; Al-Samadi A; Salo T
    Biomed Pharmacother; 2024 Jun; 175():116719. PubMed ID: 38749173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A direct comparison of selective BH3-mimetics reveals BCL-X
    Bierbrauer A; Jacob M; Vogler M; Fulda S
    Br J Cancer; 2020 May; 122(10):1544-1551. PubMed ID: 32203216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination p53 activation and BCL-x
    Bell HL; Blair HJ; Jepson Gosling SJ; Galler M; Astley D; Moorman AV; Heidenreich O; Veal GJ; van Delft FW; Lunec J; Irving JAE
    Leukemia; 2024 Jun; 38(6):1223-1235. PubMed ID: 38600316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The identification of BCL-XL and MCL-1 as key anti-apoptotic proteins in medulloblastoma that mediate distinct roles in chemotherapy resistance.
    Fitzgerald MC; O'Halloran PJ; Kerrane SA; Ní Chonghaile T; Connolly NMC; Murphy BM
    Cell Death Dis; 2023 Oct; 14(10):705. PubMed ID: 37898609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonizing Bcl-2 family members sensitizes neuroblastoma and Ewing's sarcoma to an inhibitor of glutamine metabolism.
    Olsen RR; Mary-Sinclair MN; Yin Z; Freeman KW
    PLoS One; 2015; 10(1):e0116998. PubMed ID: 25615615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF
    Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M
    Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells.
    Kawauchi D; Ogg RJ; Liu L; Shih DJH; Finkelstein D; Murphy BL; Rehg JE; Korshunov A; Calabrese C; Zindy F; Phoenix T; Kawaguchi Y; Gronych J; Gilbertson RJ; Lichter P; Gajjar A; Kool M; Northcott PA; Pfister SM; Roussel MF
    Oncogene; 2017 Sep; 36(37):5231-5242. PubMed ID: 28504719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.
    Bate-Eya LT; den Hartog IJ; van der Ploeg I; Schild L; Koster J; Santo EE; Westerhout EM; Versteeg R; Caron HN; Molenaar JJ; Dolman ME
    Oncotarget; 2016 May; 7(19):27946-58. PubMed ID: 27056887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonism of cytotoxic chemotherapy in neuroblastoma cell lines by 13-cis-retinoic acid is mediated by the antiapoptotic Bcl-2 family proteins.
    Hadjidaniel MD; Reynolds CP
    Mol Cancer Ther; 2010 Dec; 9(12):3164-74. PubMed ID: 21159604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL.
    Shi J; Zhou Y; Huang HC; Mitchison TJ
    Cancer Res; 2011 Jul; 71(13):4518-26. PubMed ID: 21546570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma.
    Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW
    Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic cell transfer of c-Myc and Bcl-2 induces large-cell anaplastic medulloblastomas in mice.
    Jenkins NC; Rao G; Eberhart CG; Pedone CA; Dubuc AM; Fults DW
    J Neurooncol; 2016 Feb; 126(3):415-24. PubMed ID: 26518543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-Myc overexpression sensitizes Bim-mediated Bax activation for apoptosis induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through regulating Bcl-2/Bcl-xL expression.
    Jiang X; Tsang YH; Yu Q
    Int J Biochem Cell Biol; 2007; 39(5):1016-25. PubMed ID: 17331788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.